135 related articles for article (PubMed ID: 37418629)
1. Cost-effective In Vivo and In Vitro Mouse Models for Evaluating Anticryptosporidial Drug Efficacy: Assessing Vorinostat, Docetaxel, and Baicalein.
Liu M; Zhang D; Wang D; Wu X; Zhang Y; Yin J; Zhu G
J Infect Dis; 2023 Nov; 228(10):1430-1440. PubMed ID: 37418629
[TBL] [Abstract][Full Text] [Related]
2. The Existing Drug Vorinostat as a New Lead Against Cryptosporidiosis by Targeting the Parasite Histone Deacetylases.
Guo F; Zhang H; McNair NN; Mead JR; Zhu G
J Infect Dis; 2018 Mar; 217(7):1110-1117. PubMed ID: 29300993
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of chitosan, a natural polysaccharide, against Cryptosporidium parvum in vitro and in vivo in neonatal mice.
Mammeri M; Chevillot A; Thomas M; Polack B; Julien C; Marden JP; Auclair E; Vallée I; Adjou KT
Exp Parasitol; 2018 Nov; 194():1-8. PubMed ID: 30237052
[TBL] [Abstract][Full Text] [Related]
4. A high-throughput phenotypic screen identifies clofazimine as a potential treatment for cryptosporidiosis.
Love MS; Beasley FC; Jumani RS; Wright TM; Chatterjee AK; Huston CD; Schultz PG; McNamara CW
PLoS Negl Trop Dis; 2017 Feb; 11(2):e0005373. PubMed ID: 28158186
[TBL] [Abstract][Full Text] [Related]
5. A Novel Piperazine-Based Drug Lead for Cryptosporidiosis from the Medicines for Malaria Venture Open-Access Malaria Box.
Jumani RS; Bessoff K; Love MS; Miller P; Stebbins EE; Teixeira JE; Campbell MA; Meyers MJ; Zambriski JA; Nunez V; Woods AK; McNamara CW; Huston CD
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29339392
[TBL] [Abstract][Full Text] [Related]
6. Long-lasting anticryptosporidial activity of nitazoxanide in an immunosuppressed rat model.
Li X; Brasseur P; Agnamey P; Leméteil D; Favennec L; Ballet JJ; Rossignol JF
Folia Parasitol (Praha); 2003 Mar; 50(1):19-22. PubMed ID: 12735719
[TBL] [Abstract][Full Text] [Related]
7. A cysteine protease inhibitor rescues mice from a lethal Cryptosporidium parvum infection.
Ndao M; Nath-Chowdhury M; Sajid M; Marcus V; Mashiyama ST; Sakanari J; Chow E; Mackey Z; Land KM; Jacobson MP; Kalyanaraman C; McKerrow JH; Arrowood MJ; Caffrey CR
Antimicrob Agents Chemother; 2013 Dec; 57(12):6063-73. PubMed ID: 24060869
[TBL] [Abstract][Full Text] [Related]
8. Development of particulate drug formulation against C. parvum: Formulation, characterization and in vivo efficacy.
Blanco-García E; Guerrero-Callejas F; Blanco-Méndez J; Gómez-Couso H; Luzardo-Álvarez A
Eur J Pharm Sci; 2016 Sep; 92():74-85. PubMed ID: 27381880
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of mangiferin against Cryptosporidium parvum in a neonatal mouse model.
Perrucci S; Fichi G; Buggiani C; Rossi G; Flamini G
Parasitol Res; 2006 Jul; 99(2):184-8. PubMed ID: 16547730
[TBL] [Abstract][Full Text] [Related]
10. Curcumin: A promising treatment for Cryptosporidium parvum infection in immunosuppressed BALB/c mice.
Asadpour M; Namazi F; Razavi SM; Nazifi S
Exp Parasitol; 2018 Dec; 195():59-65. PubMed ID: 30385266
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of nitazoxanide and paromomycin in biliary tract cryptosporidiosis in an immunosuppressed gerbil model.
Baishanbo A; Gargala G; Duclos C; François A; Rossignol JF; Ballet JJ; Favennec L
J Antimicrob Chemother; 2006 Feb; 57(2):353-5. PubMed ID: 16361328
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of treatment with paromomycin, azithromycin, and nitazoxanide in a patient with disseminated cryptosporidiosis.
Giacometti A; Burzacchini F; Cirioni O; Barchiesi F; Dini M; Scalise G
Eur J Clin Microbiol Infect Dis; 1999 Dec; 18(12):885-9. PubMed ID: 10691200
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy of curcumin and paromomycin against Cryptosporidium parvum infection in a BALB/c model.
Asadpour M; Namazi F; Razavi SM; Nazifi S
Vet Parasitol; 2018 Jan; 250():7-14. PubMed ID: 29329627
[TBL] [Abstract][Full Text] [Related]
14. Development of an immunocompetent mouse model susceptible to Cryptosporidium tyzzeri infection.
Huang Y; Song Y; You Y; Mi R; Han X; Gong H; Chen Z; Liu Y
Parasite Immunol; 2021 Jan; 43(1):e12800. PubMed ID: 33068486
[TBL] [Abstract][Full Text] [Related]
15. Bobel-24 activity against Cryptosporidium parvum in cell culture and in a SCID mouse model.
Rueda C; Fenoy S; Simón F; Del Aguila C
Antimicrob Agents Chemother; 2008 Mar; 52(3):1150-2. PubMed ID: 18160525
[TBL] [Abstract][Full Text] [Related]
16. Amixicile Reduces Severity of Cryptosporidiosis but Does Not Have
Bartelt LA; Bolick DT; Kolling GL; Stebbins E; Huston CD; Guerrant RL; Hoffman PS
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30297368
[No Abstract] [Full Text] [Related]
17. Chemoprophylaxis of Cryptosporidium parvum infection with paromomycin in kids and immunological study.
Mancassola R; Reperant JM; Naciri M; Chartier C
Antimicrob Agents Chemother; 1995 Jan; 39(1):75-8. PubMed ID: 7695333
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of curative anticryptosporidial activity of paromomycin in a dexamethasone-treated rat model.
Verdon R; Polianski J; Gaudebout C; Marche C; Garry L; Pocidalo JJ
Antimicrob Agents Chemother; 1994 Jul; 38(7):1681-2. PubMed ID: 7979310
[TBL] [Abstract][Full Text] [Related]
19. Development of Two Mouse Models for Vaccine Evaluation against Cryptosporidiosis.
Dayao DA; Jaskiewcz J; Lee S; Oliveira BC; Sheoran A; Widmer G; Tzipori S
Infect Immun; 2022 Jul; 90(7):e0012722. PubMed ID: 35735982
[TBL] [Abstract][Full Text] [Related]
20. Novel treatment strategies and drugs in development for cryptosporidiosis.
Chavez MA; White AC
Expert Rev Anti Infect Ther; 2018 Aug; 16(8):655-661. PubMed ID: 30003818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
